Single and double high-dose chemotherapy with autologous stem cell transplantation in children with advanced solid tumours: First experience;Einfache und doppelte hochdosis-chemotherapie mit autologer stammzelltransplantation bei kindern mit fortgeschrittenen soliden tumoren: Erste erfahrungen

Schweizerische Medizinische Wochenschrift

Volumn 130, Issue 12, 2000, Pages 419-425

  Kuhne T ^a   Staehelin, F ^b   Avoledo, P ^b   Tichelli, A ^b   Passweg, J ^b   Imbach, P ^b   Gratwohl, A ^b  

^a Abteilung Onkologie/Hamatologie   (Switzerland)

^b NONE

Author keywords

Autologous peripheral blood stem cells; Child; High dose chemotherapy; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADVANCED CANCER; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; NEUROBLASTOMA; NEUTROPHIL; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTE COUNT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASMS; PARENTERAL NUTRITION, TOTAL; PLATELET TRANSFUSION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034712531     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:127-8.
2. Imbach P, Odavic R, Bleher EA, Bucher U, Deubelbeiss KA, Wagner HP. Autologe Knochenmark-Reimplantation bei Kindern mit fortgeschrittenem Tumor. Schweiz Mcd Wochenschr 1979;109:283-7.
3. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr. Increasing the therapeutic response rate to anticancer drugs by applying the basic principles of pharmacology. Cancer 1984;54:1160-7.
4. Hryniuk WM, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
5. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancer 1996;347:353-7.
6. Kawano Y, Takaue Y, Watanabe T, Abe T, Okamoto Y, Iwai A, et al. Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. Cancer Res 1999;59:3321-4.
7. Tichelli A, Passweg J, Hoffmann T, Giegor M, Kühne T, Favre G, et al. Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Br J Haematol 1999;106:152-8.
8. +CD33 cells influence days to engraftment and transfusions requirements in antologous blood stem cell recipients. J Clin Oncol 1998;16:2093-104.
9. Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992;10:464-73.
10. Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, Takai K, et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem-cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant 1998;22:7-12.
11. Cairo MS. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. Sem Oncol 1995;22:23-7.
12. Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C., et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 1996;14: 2495-503.
13. Mahoney DH, Strother D, Camitta B, Bowen T, Ghim T, Pick T, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 1996;14:382-8.
14. Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994;73:1716-20.
15. Pein F, Michon J, Valtean-Couanet D, Quintana E, Frappaz D, Vannier JP, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French society of pediatric oncology study. J Clin Oncol 1998;16:3295-301.
16. Attal M, Haroussean JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
17. Blay J, Gomez F, Sebhan C, Bachelot T, Biron P, Guglielmi C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Bllod 1998;92:3562-8.
18. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73.
19. Ladenstein R, Philip T, Gadner H. Autologous stem-cell transplantation for solid tumors in children. Curr Opin Pediatr 1997;9:55-69.
20. Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N. Autologous stem-cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 1999;24:609-15.
21. Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17:2796-803.
22. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995;13:2547-55.
23. Weaver CM, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
24. Philip T, Ladenstein R. Lasset C, Hartmann O, Zucker JM, Pinkerton R, et al. 1070 myeloablative megatherapy procedures followed by stem-cell rescue for neuroblastoma: 17 years of European experience and conclusions. European group for boold and marrow transplant registry solid tumour working party. Eur J Canter 1997;33:2130-5.
25. Hero B, Kremens B, Klingebiel T, Bender-Götze C, Burdach S, Schrappe M, et al. Does megatherapy contribute to survival in metastatic neuroblastoma? Klin Pudiat 1997;209: 196-200.
26. Fröhlich B, Ahrens S, Burdach S, Klingebiel T, Ladenstein R, Paulussen M, et al. Hochdosistherapie. bei primär metastasiertem und rezidivertem Ewing-Sarkom. Klin P̈adiatr 1999; 211:284-90.
27. Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Gotze C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/ Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:227-31.
28. Walterhouse DO, Hoover ML, Marymont MA, Kletzel M. High-dose chemotherapy followed by peripheral blood stemcell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital. Med Pediatr Oncol 1999;32:88-92.
29. Ladenstein R, Gadner H, Hartmann O, Pico J, Biron P, Thierry P. The European experience with megadose therapy and autologous bone marrow transplantation in solid tumors with poor prognosis Ewing sarcoma, germ-cell tumors and brain tumors. Wien Med Wochenschr 1995;145:55-7.
30. Dupuis-Girod S, Hartmann O, Benhamou E., Doz F, Mechinaud F, Bouffet E, et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 1996;27:87-98.
31. Mason WP, Grovas A, Halpern S, Dunkel IJ, Garvin J, Heller C, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210-1.
32. Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH, Bostrom BC, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998;16:222-8.
33. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
34. Philip T, Landenstein R, Zucker JM, Pinkerton R, Bouffet E, Louis D, et al. Double megarherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993;67:119-27.
35. Chan KW, Petropoulos D, Choroszy M, Herzog C, Jaffe N, Ater J, et al. High-dose sequential chemotherapy and autologous stem-cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant 1997;20:1039-43.